Use of DF3/MUC1 regulated expression in gene therapy

Details Use of DF3/MUC1 regulated expression in gene therapy Use of DF3/MUC1 regulated expression in gene therapy

2007-07-24

2007-07-24

Whiteman, Brian (Department: 1635)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

Reexamination Certificate

active

10244705

ABSTRACT:
The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3/MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tumor cells. In addition, therapeutic genes and adjunct therapies further increase anti-tumor efficacy.

REFERENCES:
patent: 5506343 (1996-04-01), Kufe
patent: 5712136 (1998-01-01), Wickham et al.
patent: 5744144 (1998-04-01), Finn et al.
patent: 5772995 (1998-06-01), Fakharai et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 5817481 (1998-10-01), Rood
patent: 5821080 (1998-10-01), Everett et al.
patent: 5827666 (1998-10-01), Finn et al.
patent: 5846746 (1998-12-01), Gipson
patent: 5856112 (1999-01-01), Marley et al.
patent: 5858360 (1999-01-01), Fukuda
patent: 5876735 (1999-03-01), Reed
patent: 5879687 (1999-03-01), Reed
patent: 5880267 (1999-03-01), Fukuda
patent: 5885806 (1999-03-01), Dropulic et al.
patent: 5888497 (1999-03-01), Jain et al.
patent: 5888767 (1999-03-01), Dropulic et al.
patent: 5891432 (1999-04-01), Hoo
patent: 5891651 (1999-04-01), Roche et al.
patent: 5910451 (1999-06-01), Fukuda
patent: 5922836 (1999-07-01), Watson et al.
patent: 5925568 (1999-07-01), Comer et al.
patent: 5929222 (1999-07-01), Lindemann et al.
patent: 5962311 (1999-10-01), Wickham et al.
patent: 5965381 (1999-10-01), van der Bruggen et al.
patent: 6001349 (1999-12-01), Panicali et al.
patent: 6013268 (2000-01-01), Reed
patent: 6045802 (2000-04-01), Schlom et al.
patent: 6051218 (2000-04-01), McBride
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6060064 (2000-05-01), Adams et al.
patent: 6070126 (2000-05-01), Kokolus et al.
patent: 6080725 (2000-06-01), Marciani
patent: 6111087 (2000-08-01), Rethwilm et al.
patent: 6114129 (2000-09-01), Agrawal et al.
patent: 6114141 (2000-09-01), Dropulic et al.
patent: 6120763 (2000-09-01), Fakhrai et al.
patent: 6432700 (2002-08-01), Henderson et al.
patent: 6841538 (2005-01-01), Joshi et al.
patent: 2002/0045261 (2002-04-01), Snyder et al.
patent: 2003/0068307 (2003-04-01), Yu et al.
Vile et al., Gene Therapy, vol. 7, pp. 2-8, 2000.
Verma, Nature, vol. 389, pp. 239-242, 1997.
Anderson et al., Nature, vol. 392, pp. 25-30, Apr. 1998.
Ring et al. Gene Therapy, 4:1045-1052, 1997.
Abe and Kufe, “Characterizaton of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUCI) gene,”Proc. Nat'l Acad. Sci. U.S.A., 90:282-286, 1993.
Abe and Kufe, “Identification of a family of high molecular weight tumor-associated glycoproteins,”J. Immunol., 139:257-261, 1987.
Abe and Kufe, “Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells,”J. Cell. Physiol., 143:226-231, 1990.
Advani et al., “Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors,”Cancer Res., 59:2055-2058, 1999.
Batra et al., “Transfection of the human MUC 1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Pane1: integration, expression and ultrastructural changes,”J. Cell Sci., 100:841-849, 1991.
Berglund et al., “Semliki Forest virus expression system: production of conditionally infectious recombinant particles,”Biotechnology, 11:916-920, 1993.
Botti et al., “Effects of steroid-free fetal serum and steroid supplementation on MUC1 gene expression in human breast cancer cell line MCF7,”Anticancer Res., 17:205-208, 1997.
Chen et al., “Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter,”J. Clin. Invest., 96:2775-2782, 1995.
Chmura et al., “Strategies for enhancing viral-based gene therapy using ionizing radiation,”Radiat. Oncol. Investig., 7:261-269, 1999.
Dion et al., “E1A RNA transcripts amplify adenovirus-mediated tumor reduction,”Gene Ther., 3:1021-1025, 1996.
Friedman et al., “Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinoma,”Cancer Res., 46:5189-5194, 1986.
Hareuveni et al., “Vaccination against tumor cells expressing breast cancer epithelial tumor antigen,”Proc. Nat'l Acad. Sci. U.S.A., 87:9498-9502, 1990.
Heise and Kirn, “Replication-selective adenoviruses as oncolytic agents,”J. Clin. Invest., 105:847-851, 2000.
Ho et al., “Heterogeneity of Mucin gene expression in normal and neoplastic tissues,”Cancer Res., 53:641-651, 1993.
Jarrard et al , “MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis,”Cancer Res., 58:5582-5588, 1998.
Kufe et al., “Differential reactivity of a novel monclonal antibody (DF3) with human malignant versus benign breast tumors,”Hybridoma, 3:223-232, 1984.
Kurihara et al., “Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen,”J. Clin. Invest., 106:763-771, 2000.
Lancaster et al., “Structure and expression of the human polymorphic epithelial mucin gene: expressed VNRT unit,”Biochem. Biophys. Res. Commun., 173:1019-1029, 1990.
Manome et al., “Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganiciclovir,”Cancer Res., 54:5408-5413, 1994.
Metzgar et al., “Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adeoncarcinoma,”Proc. Nat'l Acad. Sci. USA, 81:5242-5246, 1984.
Miyatake et al., “Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo,”Gene Ther., 6:564-572, 1999.
Parker et al., “From the cover: engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors,”Proc. Natl. Acad. Sci. USA, 97:2208-2213, 2000.
Patterson and Harris, “Molecular chemotherapy for breast cancer,”Drugs Aging, 14:75-90, 1999.
Rodriguez et al., “Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells,”Cancer Res., 57:2559-2563, 1997.
Smyth et al., “Use of the 5′-flanking region of the mouse perforin gene to express human Fc gamma receptor I in cytotoxic T lymphocytes,”J. Leukoc Biol., 55:514-522, 1994.
Spicer et al., “Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism,”J. Biol. Chem., 266:15099-15109, 1991.
Swallow et al., “The hypervariable gene locus PUM, which codes for the tumour associated epithelial mucins, is located on chromosome 1, within the region 1q21-24,”Ann. Hum. Genet., 51:289-294, 1987.
Todo et al., “Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy,”Hum Gene Ther., 10:2869-2878, 1999.
Todo et al., “Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus,”Hum Gene Ther., 10:2741-2755, 1999.
Treon et al., “MUC-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone,”Blood, 93:1287-1298, 1999.
Uchida, “In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy,”Urology, 58(2 Suppl 1):132-139, 2001.
Varda-Bloom, “Tissue-specific gene therapy directed

Affiliated with

Also associated with

Rating

Use of DF3/MUC1 regulated expression in gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of DF3/MUC1 regulated expression in gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of DF3/MUC1 regulated expression in gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3797636